Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension and PML safety monitoring study of etrolizumab in moderate to severe active Crohn's disease
MOH_2017-07-23_000661Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Etrolizumab in Crohn's disease (2 arms), sponsored by Roche. Primary endpoint: Long-term safety and tolerability. Started Sep 2015; status: completed.
02
Drugs
Etrolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2017-07-23_000661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-23_000661.